Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology
Cancer Pain
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
A Multi-Center Study to Evaluate the Safety and Efficacy an Investigational Medication for the Treatment of Breakthrough Cancer Pain
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
“A PIVOTAL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF MR-GUIDED FOCUSED ULTRASOUND TREATMENT OF METASTATIC BONE TUMORS FOR THE PALLIATION OF PAIN IN PATIENTS WHO ARE NOT CANDIDATES FOR RADIATION THERAPY.”
Breakthrough Cancer Pain Study
Cancer Induced Bone Pain Study
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Research study of an experimental pain medication for patients with pain related to cancer.
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.
Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
